Project Grant R01AI194568
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This $256,808 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The University of Washington is conducting this research, which focuses on analyzing altered mRNA splicing in SLE neutrophils and exploring the consequences of these splicing changes, including...
- This federal Project Grant award for $3,364,935.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to functionally and mechanistically characterize genetic factors that contribute to the development of systemic lupus erythematosus (SLE). The research aims to elucidate the role of autophagy, a cellular process, in the pathogenesis of SLE, particularly in immune cells and...
- This $558,045 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate how the enzyme protein phosphatase 2A (PP2A) controls the function of T cells and contributes to the development of systemic lupus erythematosus (SLE). The research aims to determine how PP2A regulates metabolic enzymes involved in...
- This federal Project Grant award in the amount of $700,000.00, provided by the National Institute of General Medical Sciences (CFDA 93.859 - Biomedical Research and Research Training program), supports research to investigate the role of the ARID3A protein in systemic lupus erythematosus (SLE) and other autoimmune diseases. The award will fund a research project at the University of Oklahoma Health Sciences Center to: 1) define genes and epigenetic regions directly regulated by ARID3A expression...
- The federal Project Grant award of $300,000 was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to Temple University in Philadelphia, PA. The funding supports research focused on understanding the role of the kallikrein-kinin system and its ability to suppress the type I interferon response, which is a hallmark of systemic lupus erythematosus (SLE). The research aims to explore new pathways for interferon suppression and their...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,774.00 to the University of Alabama at Birmingham (UAB) over a 5-year period starting November 19, 2024. The award supports research to investigate the role of the aryl hydrocarbon receptor (AhR) pathway in regulating the development of T-bet+ B cells, which are implicated in the pathogenesis of systemic lupus...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Biotherapeutics, Inc., a clinical-stage biotechnology company in Blacksburg, Virginia. The funding will support the development of a novel oral small molecule therapeutic for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease affecting 1.5 million Americans. The company has identified a novel...
- This Project Grant award of $423,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop novel antibodies that target autoreactive B cells as a potential therapeutic approach for treating systemic lupus erythematosus (SLE) patients, particularly among the African American population. The key objectives are to determine the autoantigen specificity and clinical relevance of...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is supporting the development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat systemic lupus erythematosus (SLE). The total funding amount is $994,978, with the award period running from Aug 7, 2025 to Jul 31, 2028. The awardee, Trethera Corp, is a clinical-stage...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the cellular and molecular mechanisms by which a specific genetic variant of the IFIH1 gene (IFIH1R) promotes the development of systemic lupus erythematosus (SLE). The $2,430,679 award, with a performance period from September 2025 to August 2029, will be used by the...